URINARY MELATONIN IN RELATION TO POSTMENOPAUSAL BREAST CANCER RISK ACCORDING TO MELATONIN 1 RECEPTOR STATUS

Details

• Alternative Title:
  Cancer Epidemiol Biomarkers Prev
• Personal Author:
  Devore, Elizabeth E. ; Warner, Erica T. ; Eliassen, A. Heather ; Brown, Susan B. ; Beck, Andrew H. ; Hankinson, Susan E. ; Schernhammer, Eva S.
• Description:
  Background
  
  Urinary melatonin levels have been associated with a reduced risk of breast cancer in postmenopausal women, but this association might vary according to tumor melatonin 1 receptor (MT1R) expression.
  
  Methods
  
  We conducted a nested case-control study among 1,354 postmenopausal women in the Nurses’ Health Study, who were cancer free when they provided first-morning spot urine samples in 2000–2002; urine samples were assayed for 6-sulfatoxymelatonin (aMT6s, a major metabolite of melatonin). Five-hundred fifty-five of these women developed breast cancer before May 31, 2012, and were matched to 799 control subjects. In a subset of cases, immunohistochemistry was used to determine MT1R status of tumor tissue. We used multivariable-adjusted conditional logistic regression to estimate the relative risk (RR) of breast cancer (with 95% confidence intervals [CI]) across quartiles of creatinine-standardized urinary aMT6s level, including by MT1R subtype.
  
  Results
  
  Higher urinary melatonin levels were suggestively associated with a lower overall risk of breast cancer (multivariable-adjusted RR=0.78, 95% CI=0.61–0.99, comparing quartile 4 vs. quartile 1; p-trend=0.08); this association was similar for invasive vs. in situ tumors (p-heterogeneity=0.12). There was no evidence that associations differed according to MT1R status of the tumor (e.g., p-heterogeneity for overall breast cancer=0.88).
  
  Conclusion
  
  Higher urinary melatonin levels were associated with reduced breast cancer risk in this cohort of postmenopausal women, and the association was not modified by MT1R subtype.
  
  Impact
  
  Urinary melatonin levels appear to predict the risk of breast cancer in postmenopausal women. However, future research should evaluate these associations with longer-term follow-up and among premenopausal women.
  
  
• Subjects:
  Aged Biomarkers, Tumor Breast Neoplasms Case-Control Studies Creatine Female Humans Incidence Logistic Models Longitudinal Studies Melatonin Middle Aged Postmenopause Receptor, Melatonin, MT1 Risk Factors

  More +
• Source:
  Cancer Epidemiol Biomarkers Prev. 26(3):413-419.
• Pubmed ID:
  28151704
• Pubmed Central ID:
  PMC5336486
• Document Type:
  Journal Article
• Funding:
  P01 CA087969/CA/NCI NIH HHS/United States ; R01 OH009803/OH/NIOSH CDC HHS/United States ; UM1 CA186107/CA/NCI NIH HHS/United States
• Volume:
  26
• Issue:
  3
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:5c23df01b74c29ec69fe5204db303a25cd4580d8abffac0dd59a4e8f7e112552
• Download URL:
  https://stacks.cdc.gov/view/cdc/44472/cdc_44472_DS1.pdf
• File Type:
  [PDF - 97.93 KB ]